COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

NCL Collaborators

See what our previous collaborators say about working with the NCL

“NCL worked on two projects for my lab and one of the start-ups I founded, LipocureRX LTD. In both projects, NCL studies provided invaluable characterization assistance for two liposomal products being developed at Lipocure. NCL provided extensive analysis of the physical and chemical properties of the formulations, including detailed studies on the stability and degradation products of the formulation, in vitro cytotoxicity studies in multiple cell lines, multiple in vitro immunotoxicity studies to build upon our knowledge of the formulation’s safety profile, extensive assistance in endotoxin testing, and in vitro and in vivo pharmacokinetic studies. The expert analysis of these data helped to solidify our regulatory approach for these products, and we are currently in pre-IND discussions with the FDA. Additionally, the reports we received from NCL helped us to get an approval for the first in man study we performed in Israel.“

— Yechezkel (Chezy) Barenholz, Hebrew University Hadassah Medical School

“The NCL has been pivotal for our group in the clinical translation of Rhenium Nanoliposomes and bringing this technology forward for our patients. As part of the Pre-IND process, the Food and Drug Administration requested validation of our manufacturing techniques and additional drug characterization. This work was undertaken by the NCL, provided as part of the CMC section of our IND, and resulted in a successful IND application. Rhenium Nanoliposomes are now completing phase 1 clinical trial, with phase 2 planned to begin within the year. We are extremely grateful for the expertise provided by the NCL.“

— Andrew Brenner MD, PhD, University of Texas Health Science Center

“ZY Therapeutics’ collaboration with NCL has enabled us to successfully advance ZY-010-PNP from discovery-phase toward a pending IND filing. In addition to the NCL team’s broad expertise in nanotechnology, open and concrete communications between NCL and ZY have proven critical to our progress. The NCL team’s input has helped us resolve several key technical issues, including an effective method to control endotoxin levels in ZY’s polymer which optimized our CMC process to meet standards for injectable formulations. Increased understanding of our formulation’s release kinetics, performed via NCL’s stable isotope tracer ultrafiltration assay (SITUA), solidified our development strategy with this drug candidate. Most importantly, NCL shared with us their passion in finding improved therapy for cancer patients.

ZY technical team’s collaboration with NCL on the development of ZY-010-PNP has significantly reduced our cost and increased the development speed for this promising therapy. Without NCL input, we might still be struggling with many issues associated with natural complexity with nano-formulation.“

— Jun Li, Co-founder and CSO, ZY Therapeutics, Inc.

"Working with the NCL was a valuable and educational experience. Their experienced and professional team characterized our formulation using numerous assays that cover a range of analytical testing parameters, many of which are critical but would not have occurred to me. Overall, the NCL greatly advanced our product development and we have subsequently been able to have a pre-IND meeting with the FDA."

— Jon Lovell, Associate Professor, University at Buffalo

"The NCL cascade assay was very useful to Nanobiotix for the development of one of our intravenously administered nanomedicine products. NCL's collaborative approach, from application through completion, was instrumental to our efforts. NCL adapted their characterization process to fit the needs of our project, tailored smart protocols to answer our questions in a timely manner, and provided meaningful results and suggestions throughout. Given this experience, we highly recommend application to the NCL cascade assay for companies aiming to accelerate product development. "

— Matthieu Germain, Nanobiotix

“NCL provided top quality characterization and evaluation of a nanocarrier intended for chemotherapy delivery in pancreas and colon cancer. The characterization was well planned, executed and we received comprehensive and detailed feedback that was extremely valuable in improving the safety and performance characteristics of our carrier. The NCL scientists indeed showed in-depth understanding of how to evaluate the characteristics and operational features of nano-enabled drug delivery systems, in vitro and in vivo. The interaction with the staff was pleasant and it was a real pleasure collaborating with NCL. NCL clearly constitutes one of the top places in the world to have. Nanomaterial is characterized for therapeutic use”.

— Andre Nel, Distinguished Professor of Medicine, UCLA

"This is a top quality nano characterization facility in the world. NCL has assembled the expertise that is crucial for translational nanomedicine. It includes the intellectual and technical infrastructure, generating highly informative data and comprehensive report. Working with NCL is a pleasant journey – it makes someone understanding nanomaterial better and deeper. If you are looking to test your nanomaterial professionally and objectively, send in the application to NCL."

— Huan Meng, Associate Professor, UCLA

Academic Collaborators

Case Western Reserve University

Efstathios Karathanasis
Zheng-Rong Lu

Cedars-Sinai Medical Center

John Yu

Dartmouth College

P. Jack Hoopes

Duke University

Ashutosh Chilkoti

Emory University

Shuming Nie
Lily Yang

Fred Hutchinson Cancer Research Center

Matthias Stephan

Georgia Tech Research Corporation

John McDonald

Georgetown University

Esther Chang

Hebrew University

Yechezkel (Chezy) Barenholz

Houston Methodist Reaserch Institute

Mauro Ferrari

Imperial College London

Andrew Miller

Johns Hopkins University

Jordan Green
Anirban Maitra

Lankenau Institute for Medical Research

Janet Sawicki

Massachusetts Institute of Technology

Daniel Anderson

Northeastern University

Mansoor Amiji
Vladimir Torchilin

Northwestern University

C. Shad Thaxton

Ohio State University

Robert Lee
Peixuan Guo

Penn State College of Medicine - Penn State Hershey

James Conner
Mark Kester

Princeton University

Robert Prud'homme

Purdue University

Alex Wei

Rutgers, the State University of New Jersey

Joachim Kohn

Shaare Zedek Medican Center

Alberto Gabizon

Stanford University

Raag Airan
Heike Daldrup-Link
Sanjiv (Sam) Gambhir

Texas A&M

Eric Simanek

University at Buffalo - SUNY

Jonathan Lovell

University of California, Davis

Katherine Ferrara
Chong-xian Pan

University of California, Santa Barbara

Erkki Ruoslahti

University of California, Los Angeles

Andre Nel & Huan Meng
Lenny Rome

University of Chicago

Yusuke Nakamura

University of Iowa

Aliasger Salem

University of Michigan

Raul Kopelman
Martin Philbert
James Moon
Anna Schwendeman

University of Missouri - Columbia

Kattesh Katti

University of North Carolina

Alexander Kabanov
Russ Mumper
William Zamboni

University of South Florida

Ed Turos

University of Texas, Health Science Center

Andrew Brenner

University of Texas MD Anderson Cancer Center

Chun Li
Anil Sood

University of Utah

Jindrich Kopecek

University of Washington

Miqin Zhang

University of Wisconsin Madison

Darin Furgeson

Virginia Commonwealth University

Devanand Sarkar

Wake Forest School of Medicine

William Gmeiner

Washington University

Samuel Achilefu

Corporate Collaborators

AADi Bioscience

Alnis Biosciences

Altus Formulation

Amgen

Arrowhead Pharmaceuticals

AstraZeneca

Avidea Technologies

Avidimer Therapeutics

Azaya Therapeutics

Bexion Pharmaceuticals

BIND Therapeutics

Bio-Synectics, Inc.

Carigent Therapeutics

Celator Pharmaceuticals

City of Hope

Co-D Therapeutics

Cureport, Inc.

CuriRx

CytImmune

Dendritic Nanotechnologies

EGEN

Ensysce Biosciences

Eunoia Biotech

Evident Technologies, Inc. 

GE Global Research

Intezyne Technologies

Kereos

Labopharm, Inc.

Lipocure, Ltd.

Luna Innovations

Merck KGaA

Merrimack Pharmaceuticals

Nanobiotix

NanoHybrids

Nanoprobes

NanoScan Imaging

Nanospectra Biosciences

Nanovalent Pharmaceuticals

Nemucore Medical Innovations

Oncolmmune, Inc.

Ontario Institute for Cancer Research (OICR)

Panacea Biotech

Parabon NanoLabs

PDS Biotechnology

PeptiMed, Inc.

Pfizer

ProNAi Therapeutics

Proteogenomics Research Institute

Qualiber Inc.

Rexahn Pharmaceuticals

Seva Therapeutics

Signpath Pharma

Siva Therapeutics

SN BioScience

SynerGene Therapeutics, Inc.

Tego Biosciences

ZY Therapeutics, Inc.

 

Government Collaborators

The FDA’s Center for Biologics Evaluation and Research (FDA CBER)

The FDA’s Center for Devices and Radiological Health (FDA CDRH)

The FDA’s Center for Drug Evaluation and Research (FDA CDER)

The FDA’s Center for Food Safety and Applied Nutrition (FDA CFSAN)

The FDA’s National Center for Toxicological Research (FDA NCTR)

The FDA’s Office of Generic Drugs (FDA OGD)

The NCI’s Center for Cancer Research

The National Institute of Environmental Health Sciences (NIEHS)

The United States Army Center for Environmental Health Research (USACEHR)

The United States Army Medical Research Institute for Infectious Diseases (USAMRIID)